Streptococcus pneumoniae remains a major public health hazard. Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited serotype coverage, long-lasting protection, and lower cost to be developed. One of the most promising candidates is the Whole-Cell Pneumococcal Vaccine (WCV). The new generation of whole-cell vaccines is based on an unencapsulated serotype that allows the expression of many bacterial antigens at a lower cost than a recombinant vaccine. These vaccines have been extensively studied, are currently in human trial phase 1/2, and seem to be the best treatment choice for pneumococcal diseases, especially for developing countries.
Pneumococcal Antigens
The CPS is the most surface-accessible structure of Streptococcus pneumoniae and resembles an accumulation of viscous material. It is a high-molecular-weight polymer composed of repeating units of oligosaccharides. Capsules of most capsular types are covalently bonded to the cell wall [20] . The CPS helps protect pneumococci from several of the host defense mechanisms [4] . Serotypes differ in both chemical composition and CPS amount. These characteristics are related to the virulence degree, invasiveness, and the survival ability of the bacteria in the circulation of different pneumococcal strains [21, 22] .
Besides the diversity of the CPS among S. Pneumoniae strains, other highly conserved cell proteins contribute to the virulence of pneumococcus [23] . The main proteins and their functions are shown in Table 1 . Many of these proteins have been extensively examined as vaccine candidate antigens, because CPS-conjugated protein vaccines are of a specific serotype and do not cover the emergence of new virulent serotypes [3] . Table 1 . Main proteins that contribute to the virulence of pneumococcus and their functions.
Protein Localization Function References
Ply Exotoxin Cytotoxic, TLR4 agonist, complement activator [24, 25] PspA Surface Protein
Inhibits the activation of the complement, binds to lactoferrin, helping adherence and protecting bacteria from lactoferrin toxic effects. [24, 25] PspC Surface Protein Adhesin, inhibits activation of complement binding factor H [24, 25] PcpA Surface Protein Adhesin, Choline binding protein [26] PhtD Surface Lipoprotein Adhesin, Zn binding protein [27, 28] Autolysin Cytoplasm/Cell Wall Autolytic response induced during the stationary growth phase [29] PiuA Surface Lipoprotein Iron uptake ABC transporter [25] PiaA Surface Lipoprotein Iron uptake ABC transporter [25] PsaA Surface Lipoprotein Mn + 2 uptake ABC transporter adhesin [30] Pilus Surface Protein Epithelial cell adhesion [23] Ply (pneumolysin); PspA (pneumococcal surface protein A); PspC (pneumococcal surface protein C); PcpA (pneumococcal choline-binding protein A); PhtD (polyhistidine triad protein D); PiuA (pneumococcal iron uptake A); PiaA (pneumococcal iron acquisition A); PsaA (Pneumococcal surface antigen A); Pilus (pilus proteins).
The first protein antigens were identified through antibody screening, and specific antibodies were found in children exposed to pneumococcus, namely pneumolysin (Ply), pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC), and pneumococcal surface antigen A (PsaA) [25] . These proteins were proposed for use in a vaccine with the capacity to induce serotype-independent antibodies and broader protective immunity against pneumococcal infections [31, 32] .
Ply is a cholesterol-binding protein that is liberated by autolysis of the bacteria and forms pores in eukaryotic membranes [25, 33] . Another important effect of Ply is activation of the innate immune system through the TLR4 and NLRP3 inflammasome [25, 34, 35] . This protein is toxic in its native form, so nontoxic variants have been generated to be used in experimental vaccines [25] .
PspA is a choline-binding protein that is attached non-covalently to the cell surface through its C-terminal choline-binding repeat region. The protein is present in all pneumococcal strains and has a variable, but cross-protective, N-terminal region exposed on the surface of the bacteria [36] . Furthermore, PspA has a conserved proline-rich region that has been shown to elicit antibody-mediated protection against invasive pneumococcal disease in mice and has been proposed for use as an antigen in a vaccine [23] . PspA inhibits the activation and deposition of the C3 complement protein on the bacterial surface, binds to lactoferrin, helps to adhere to the surface of the host, and protects bacteria from lactoferrin toxic effects [25, 37] .
PspC is a similar protein to PspA that is capable of interacting with the complement through C3 and Factor H [25, 38, 39] . PspC also has adhesion properties through interactions with sIgA and the laminin receptor [25] .
PsaA is a conserved lipoprotein that transports Mn 2+ and also functions as adhesin, which plays a major role in pneumococcal attachment to the host cell and virulence [30, 32] .
Other conserved cell-surface proteins that have been assayed as vaccine candidates include PiuA, PiaA, PcpA, PhtD and RrgB (recombinant protein from Pilus 1) [23].
Preclinical Studies
Most of these proteins were assayed alone or in combination in lab animals. Many have shown potential as future candidates for independent serotype vaccines [23, 25] .
Vaccines 2019, 7, 151 4 of 10 For example, Cecchini and coworkers reported a novel serotype-independent vaccine against S. Pneumoniae (PnuBioVax; PBV) composed of PspA, Ply (PlyD6), Pilus 1, and other virulence factors obtained from a modified TIG4 serotype culture [40] . PBV showed high levels of IgG antibodies against these proteins in immunized rabbits. The results suggest that PBV vaccination generates antibodies that have multiple mechanisms of action that provide effective protection against pneumococcal infection, independently of the serotype [41] .
Clinical Studies
Some of the formulations have previously been proven in children. In 2017, Odutola and collaborators described a two-part study conducted with a mixture of antigens to 10 pneumococcal serotype-specific polysaccharide conjugates (10 VT), combined with pneumolysin toxoid and pneumococcal histidine triad protein D (PHiD-CV/dPly/PhtD-30) [42] . The vaccine was well-tolerated by Gambian children. Furthermore, the authors assessed the efficacy of the formulations against pneumococcal nasopharyngeal carriage (NPC) prevalence in infants. Unfortunately, results did not show that the addition of pneumococcal proteins dPly and PhtD reduces the prevalence of nonserotype 10VT carriage beyond that provided by the vaccine without Ply and PhtD [42] . These results probably indicate that Ply and PhtD are not effective in relation to bacteria carriage, but PHiD-CV/dPly/PhtD-30 should not be discarded as an extended serotype vaccine for pneumonia cases.
Another trivalent recombinant candidate vaccine that comprised PhtD, Ply and PcpA was reported by Brooks and colleagues [43] . The vaccine formulations increased antibodies concentrations in adults, toddlers, and infants to all vaccine antigens. Although, in infants the use of adjuvant was necessary for a maximal immune response, the formulations were well-tolerated and no safety concerns were identified. Some other formulations have been under evaluation in clinical trials as pneumococcal vaccine GSK2189242A of GlaxoSmithKline (GlaxoSmithKline, Brentford, UK). This vaccine comprised dPly and PhtD antigens and it is currently in Phase 2 with promising results [44] .
Whole-Cell Pneumococcal Vaccine

Preclinical Assays
As an alternative to current vaccines, which have high production costs among other disadvantages, formulations with complete cells (whole-cell vaccines) express all protein antigens and could be less expensive than the purification of one or many of these proteins.
In relation to preclinical assays, in the last decade, inactivated whole cells of unencapsulated S. pneumoniae have been proposed to provide serotype-independent protection. These vaccine candidates have shown humoral and cellular immune responses against multiple antigens, giving very promising results in mouse infection-challenge models of colonization, pulmonary pneumonia, and sepsis [45] [46] [47] [48] .
Malley and coworkers tested killed, unencapsulated mutated Rx1 cells, applied intranasally with cholera toxin (CT) as an adjuvant in mice and rats. This formulation was shown to provide protection against nasopharyngeal colonization and invasive disease, using two different serotypes (6B, and 3) [45] .
Some years later, the same preparation but with a nontoxic adjuvant was assayed with promising results in a mouse colonization model with serotypes 6B, 14, and 23F [49] .
As in the clinical trials, the pneumococcal whole-cell vaccine (PWCV) used in most of the preclinical assays contained chemically killed S. pneumoniae RM200 cells [45] . The RM200 lineage is derived from the original progenitor, S. pneumoniae D39 [50] . Figure 1 shows the evolution of the cell from the original clinical isolation until now. Besides the mutations that prevent the expression of the capsule, RM200 also has another mutation: the replacement of the lytA gene with the Janus cassette autolysine to reduce virulence and improve the yield of cells; the alteration of the pneumolysin toxin gene that removes the protein's cytolytic and complement-activating activity [51, 52] . Glycoprotein PsrP, known Vaccines 2019, 7, 151 5 of 10 as pneumococcal pili, and degradative zinc metalloprotease ZmpC were also absent, and there was a nonsense mutation in the PspC gene that removed six of the eight choline-binding domains (CBDs), possibly reducing the proportion of this protein attached to the cell surface [53, 54] .
preclinical assays contained chemically killed S. pneumoniae RM200 cells [45] . The RM200 lineage is derived from the original progenitor, S. pneumoniae D39 [50] . Figure 1 shows the evolution of the cell from the original clinical isolation until now. Besides the mutations that prevent the expression of the capsule, RM200 also has another mutation: the replacement of the lytA gene with the Janus cassette autolysine to reduce virulence and improve the yield of cells; the alteration of the pneumolysin toxin gene that removes the protein's cytolytic and complement-activating activity [51, 52] . Glycoprotein PsrP, known as pneumococcal pili, and degradative zinc metalloprotease ZmpC were also absent, and there was a nonsense mutation in the PspC gene that removed six of the eight choline-binding domains (CBDs), possibly reducing the proportion of this protein attached to the cell surface [53, 54] . In 2010, using RM200 cells, Lu and coworkers developed a subcutaneous injection vaccine, which was shown to provide protection in nasal colonization models with a serotype 6B strain and a fatal aspiration sepsis model with serotypes 3 and 5 in mice [47] . In 2010, using RM200 cells, Lu and coworkers developed a subcutaneous injection vaccine, which was shown to provide protection in nasal colonization models with a serotype 6B strain and a fatal aspiration sepsis model with serotypes 3 and 5 in mice [47] .
Similarly, HogenEsch and coworkers determined the optimal formulation of an aluminumadjuvantized whole-cell pneumococcal vaccine. The authors reported that the vaccine containing aluminum phosphate (AP) adjuvant produced a higher antibody response and induced a critical IL-17 response in the prevention of nasopharyngeal colonization by S. pneumoniae [55] .
Recently, Campos and coworkers showed that PWCV from RM200 cells was capable of inducing non-capsular antibodies to protect mice against invasive pneumococcal disease and reduce nasopharyngeal (NP) carriage via IL-17A production. The authors demonstrated that PWCV antibodies were able to bind to different encapsulated strains, activate the complement, and induce phagocytosis of pneumococcus in vitro [56] .
Currently, investigations are focused on gaining a better understanding of the immunological mechanism involved in PWCV protection and providing improvements in the vaccine formulation through bacterial inactivation by gamma irradiation [48, [57] [58] [59] [60] .
Clinical Assays
Pneumococcal whole-cell vaccine clinical trials registered in the US National Library of Medicine are supported by PATH (Program for Appropriate Technology in Health) and are in phase 1/2. Phase 1 was carried out in 2012 with the main goal being to determine if a Streptococcus pneumoniae PWCV (SPWCV) given with alum is safe and well-tolerated by healthy adults (NCT01537185). There were 42 participants and only one case of a serious adverse effect was registered that was unrelated to the vaccination (ruptured ectopic pregnancy with hemorrhage). Incidences of mild reactions were similar between the vaccinated and control groups [61] . Vaccine formulations contained chemically killed S. pneumoniae RM200 cells [45] .
At the same time, immunoglobulin G (IgG) responses to SPWCV were characterized by pan proteome microarray using sera samples from 35 adult placebo-controlled phase 1 trial participants [62] . The results showed that SPWCV induced increases in the IgG binding of seventy-two functionally different proteins. The vaccine induced an IgG response in naturally immunogenic proteins expressed by the RM200. In addition, the vaccine induced specific responses to PclA, PspC, and ZmpB protein variants, whereas induced antibodies against PspA and ZmpA were recognized by a widespread set of alleles [54] .
Recently, another clinical trial (phase 1/2), "A Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-Cell Vaccine Formulated with Alum in Healthy Kenyan Young Adults and PCV-Primed Toddlers", explored these issues further (NCT02097472). The purpose of this study was to assess the safety and tolerability of a S. pneumoniae whole-cell vaccine adsorbed to Alum (PATH-wSP) administered intramuscularly to 304 healthy Kenyan adults and toddlers who had been primed with a pneumococcal conjugate vaccine (PCV). Additionally, the study explored the immunoglobulin response when PATH-wSP was administered [63] .
Preliminary results showed that the vaccine was well-tolerated. Subjects returned to the clinic one week after each vaccination, and at four weeks after the final vaccination, for assessment of solicited reactogenicity, targeted physical examination, vital signs, laboratory assessment, immunology testing, and evaluation of unsolicited adverse events and concomitant medication use. Serious adverse events occurred in less than 5% of adults and had no relation to the vaccination, while, adverse events occurred in around 4-12% of children, depending on the observed cohort, with most cases being unrelated to the vaccination.
Total adverse events were found in almost all participants, including control cohorts, and most cases were excluded from association with the vaccination [63] .
Besides this, IgG measures were taken for the selected pneumococcal proteins in all cohorts with variable results, depending on the protein [63] .
Clinical trials of effectivity of this vaccine are expected in the next few years.
Conclusions
The development of an effective pneumococcal vaccine has been a public-health topic for more than a century. The first pneumococcal vaccine was a whole-cell vaccine and, paradoxically, the next generation of vaccines could also be of the whole-cell type.
Nevertheless, there are several challenges before a protein or a whole-cell vaccines' licensure can be addressed [28] . Correlates of protection are needed to support the licensure of vaccines, for that, a network of investigators from different research centers around the world have to deliver high-quality standardized functional immune assays, studies protocols comparing the relationship between antibody concentrations and disease risk in a non-vaccinated, naturally exposed population [64,65]. All the data must establish favorable safety and follow international quality standards according to Good Clinical Practices and the World Health Organization (WHO) recommendations. The new whole-cell vaccine is based on an unencapsulated serotype, and it is expected that it will allow the generation of cellular immunological responses and many types of protective antibodies. The combination of these advantages with the vaccine's affordable cost makes it suitable for developing countries. Clinical trials showed very promising results.
On the other hand, given the crude nature (whole-cell), PWCV vaccine has more chances to induce a higher number of adverse reactions than purified antigens. Additionally, for vaccine manufacturers, the standardization and lot consistency could be more difficult to achieve with whole-cell vaccines than with purified antigens.
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